This segment focuses on the development of small molecule inhibitors and other targeted therapies designed to selectively inhibit cancer cell growth and survival. Key research and development activities include preclinical studies, Phase 1/2 clinical trials, and biomarker identification to optimize patient selection. Technologies employed include medicinal chemistry, structural biology, and advanced screening methods. The lead candidate, CLN-081, targets EGFR exon 20 insertion mutations in non-small cell lung cancer (NSCLC), addressing a significant unmet need in this patient population. The goal is to improve patient outcomes by providing more effective and less toxic treatment options. Future opportunities include expanding the application of targeted therapies to other cancer types and developing novel combination strategies. Regulatory and clinical aspects involve rigorous adherence to FDA guidelines and continuous monitoring of clinical trial data.

This segment is dedicated to developing innovative immunotherapies that harness the power of the immune system to fight cancer. Research and development efforts include the discovery and optimization of bispecific antibodies, T cell engagers, and other immune-modulating agents. Technologies used include antibody engineering, cell-based assays, and in vivo models to evaluate efficacy and safety. Preclinical products like CLN-049 (bispecific antibody for AML), CLN-619 (monoclonal antibody for solid tumors), and CLN-978 (T cell engaging antibody for B-cell malignancies) are designed to enhance immune cell activity against cancer cells. The aim is to provide durable responses and improve survival rates for patients with various types of cancer. Future opportunities involve exploring novel immune targets and developing personalized immunotherapy approaches. Clinical trials and regulatory pathways are critical components of this segment, ensuring the safety and effectiveness of these therapies.